Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erythropoietin alone versus erythropoietin plus differentiating therapy in lower-risk myelodysplastic syndrome
2006-006482-16Phase 3Completed
- Sponsor
- Fondazione Italiana Sclerosi Multipla
- Start
- May 2007
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in myelodysplastic syndrome (MDS) comparing Erythropoietin alone with Erythropoietin + isotretinoin + vitamin D3 (2 arms). Primary endpoint: Erythroid response. Started May 2007; status: completed.
02
Drugs
erythropoietinisotretinoincholecalciferol
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2006-006482-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006482-16.